<span item_type="fundamental" item_id="6165105c69d98ad96d8320aedb3d0054" counter_id="ST/US/CLYM" env="prod"></span><span item_type="announcement" item_id="515967710315090689" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.31.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: Climb Bio, Inc. did not report any revenue for the three months ended March 31, 2025, as the company is still in the clinical development phase and has not yet commercialized any products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The company reported a net loss of $20.8 million for the three months ended March 31, 2025, compared to a net loss of $1.7 million for the same period in 2024, representing an increase in net loss by $19.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li><li><strong>Research and Development Expenses</strong>: R&amp;D expenses increased significantly to $17.3 million for the three months ended March 31, 2025, from $1.1 million for the same period in 2024, primarily due to increased spending on budoprutug and CLYM116 development programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li><li><strong>General and Administrative Expenses</strong>: These expenses rose to $5.7 million for the three months ended March 31, 2025, from $1.9 million in the same period in 2024, mainly due to increased personnel-related expenses and consulting fees.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: The company used $15.4 million in net cash for operating activities during the three months ended March 31, 2025, compared to $1.8 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li><li><strong>Net Cash Used in Investing Activities</strong>: Climb Bio, Inc. used $42.8 million in net cash for investing activities during the three months ended March 31, 2025, primarily due to the purchase of marketable securities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Accumulated Deficit</strong>: As of March 31, 2025, the company had an accumulated deficit of $250.7 million, up from $229.9 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Climb Bio, Inc. plans to advance its clinical trials for budoprutug in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE), with the first patient dosing in the second half of 2025 for pMN and the first half of 2025 for ITP and SLE.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li><li><strong>Non-Core Business</strong>: The company is also developing CLYM116 for IgA nephropathy and plans to report preclinical data in the second half of 2025, with an anticipated IND submission for a Phase 1 clinical trial in the same period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li><li><strong>Priority</strong>: The company emphasizes the development of budoprutug and CLYM116 as its primary strategic focus, with significant investment in clinical trials and regulatory submissions to achieve market approval.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-20250331.htm"></span></li></ul>

Climb Bio | 10-Q: FY2025 Q1 EPS: USD -0.31